<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="http://www.genzyme.com/" target=_blank>Genzyme</A></STRONG>, a <A title="" href="http://www.sanofi.fr/l/fr/fr/index.jsp" target=_blank>Sanofi</A> Group business, made advantage of the <A title="" href="https://www.aderly.com/lyon-economic-news/only_lyon-news-THE-ECTRIMS-CONGRESS-ATTRACTS-RECORD-ATTENDANCE-7000-PARTICIPANTS,n,6916,EN.jsp" target=_blank>ECTRIMS Congress </A>to present the positive results from its Tower project, devoted to AUBAGIO.</STRONG>&nbsp;<STRONG>AUBAGIO 14 mg is the only oral MS therapy to significantly delay progression of disability across two phase III studies</STRONG>. "<EM>Slowing the progression of disability is a major goal in treating MS and remains a significant unmet need for many patients</EM>," said Ludwig Kappos, M.D., Chair of <A title="" href="https://www.aderly.com/neurosciences/index,p,163,EN.jsp" target=_blank>Neurology</A>, University Hospital Basel, Switzerland, who presented the key Tower results. "<EM><STRONG>The convenience of a once daily oral therapy offers a meaningful alternative for patients wanting to avoid the burden of regular injections</STRONG></EM>", said David Meeker, M.D., President and CEO, Genzyme. </P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>The ongoing AUBAGIO clinical development program, involving more than 5,000 patients in 36 countries, is among the largest of any MS therapy</STRONG>. The Genzyme Group specializes in innovative <A title="" href="https://www.aderly.com/technologies_medicales/index,p,220,EN.jsp" target=_blank>medical</A> products and devices applied to orphan diseases, kidney diseases, orthopaedics, <A title="" href="https://www.aderly.com/cancerologie/index,p,164,EN.jsp" target=_blank>oncology</A>, general surgery, transplantation and diagnostic testing. <STRONG>Its production plant, located in Marcy l&#8217;Etoile in the <A title="" href="https://www.aderly.com/sites-implantation/index,p,17,EN.jsp" target=_blank>Lyon region</A>, employs over 150 people</STRONG> and is in charge of the exclusive production of two drugs in the field of transplantation. <STRONG>Thanks to <A title="" href="https://www.aderly.com/services-aderly/index,p,100003,EN.jsp" target=_blank>Aderly</A>, Genzyme set up its regional headquarters in the <A title="" href="https://www.aderly.com/centre-recherche-et/biotechnology-cluster-lyon,p,21,EN.jsp" target=_blank>Lyon-Gerland</A> area in 2005.</STRONG></P> <P>&nbsp;</P>